Manufacturing Scale Exegenesis Bio operates state-of-the-art cGMP manufacturing facilities with large disposable bioreactors for viral vectors and plasmids, enabling scalable production and potential external manufacturing partnerships.

Global Clinical Footprint The company runs two clinical programs— SMA in China and neurovascular AMD in the United States—supported by its multi-region footprint, creating opportunities for regional trial material supply, regulatory collaborations, and future commercialization partnerships.

Innovative Delivery Exegenesis Bio is advancing eye and CNS gene therapies, including a next-generation ocular capsid for intravitreal delivery and capsids capable of crossing the blood–brain barrier, presenting licensing or collaboration opportunities for ophthalmology, CNS, and liver-directed programs.

Strategic Partnerships Active engagement with the industry, evidenced by multiple ASGCT presentations, positions Exegenesis as a collaborative partner for licensing, co-development, or contract manufacturing services to scale delivery platforms and accelerate program timelines.

Financial Momentum The company's disclosed revenue range and ongoing fundraising indicate financial momentum and readiness to explore out-licensing its delivery technologies, manufacturing capacity, or IP through strategic partnerships with biotechs and established gene therapy players.